DSP Mutual Fund increased its stake in Cipla Limited from 1.78% to 1.90%, purchasing 9,85,683 shares for approximately ₹128.24 Cr.
A leading pharmaceutical manufacturer, Cipla develops and markets branded and generic formulations alongside active pharmaceutical ingredients across multiple therapeutic areas. Established in 1935, the company operates manufacturing facilities across India and internationally, serving both domestic and global markets. Cipla's distinctive strength lies in its integrated business model combining formulation development with API production, enabling cost-efficient drug manufacturing, distribution, and accessibility to patients worldwide.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.
